$117 Million
Joint Bookrunner
Follow-On
January 2023
$125 Million
Joint Bookrunner
Follow-On
January 2023
UNDISCLOSED
Exclusive Financial Advisor
Strategic Investment from InTandem Capital Partners
January 2023
Up to CHF 200 MILLION
Exclusive Financial Advisor
Sale to Tandem Diabetes Care, Inc.
Pending
$500 MILLION
Joint Bookrunner
Rule 144A Convertible Senior Notes
December 2022
UNDISCLOSED
Exclusive Financial Advisor
Sale to Intuit
Pending
$60 MILLION
Joint Bookrunner
Follow-On
November 2022
$260 Million + Up to $1.8B in Milestone Payments
Exclusive Financial Advisor
Exclusive Licensing Agreements with Point Biopharma
Pending
$50 MILLION
Joint Bookrunner
Follow-On
November 2022
$575 MILLION
Joint Bookrunner
Follow-On
November 2022
$80 MILLION
Joint Bookrunner
Follow-On
November 2022
$500 MILLION
Joint Bookrunner
Follow-On
December 2022